Bausch Health Companies Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Bausch Health Companies Inc. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $0.00.
- Bausch Health Companies Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $0.00.
- Bausch Health Companies Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $675.00M.
- Bausch Health Companies Inc. stock issued during period, value, new issues for the quarter ending 2015-12-31 was $1.00M.
- Bausch Health Companies Inc. stock issued during period, value, new issues for fiscal 2022 was $675.00M.
- Bausch Health Companies Inc. stock issued during period, value, new issues for fiscal 2013 was $2.31B.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $675.00M 10-K · filed 2025-02-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2022-06-30 | $675.00M 10-Q · filed 2023-08-03 | |
| 2015-12-31 | $1.00M derived: 8-K 12 month − 10-Q 9 month · filed 2018-08-10 | $1.48B 8-K · filed 2018-08-10 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | |
| 2015-06-30 | $49.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | |
| 2015-03-31 | $1.43B 10-Q · filed 2016-06-07 | |
| 2013-12-31 | $37.60M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $2.31B 10-K · filed 2016-04-29 |
| 2013-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |